-
EP4225352
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4225352
| EP4225352 - METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 14.07.2023 Database last updated on 14.06.2024 | |
| Former | The international publication has been made Status updated on 16.04.2022 | Most recent event Tooltip | 15.12.2023 | Change: Validation states | published on 17.01.2024 [2024/03] | 15.12.2023 | Change - extension states | published on 17.01.2024 [2024/03] | Applicant(s) | For all designated states Dr. Mary Morris & Associates, LLC 822 Country Club Lane Onalaska, WI 54650 / US | For all designated states Saint Louis University 221 North Grand Blvd. St. Louis, MO 63110 / US | [2023/35] |
| Former [2023/33] | For all designated states Dr. Mary Morris & Associates, LLC 822 Country Club Lane Onalaska, WI 54650 / US | ||
| For all designated states Saint Louis University 220 North Grand St. Louis, MO 63110 / US | Inventor(s) | 01 /
MORRIS, Mary S. Onalaska, Wisconsin 54650 / US | 02 /
DI PAOLO, Richard St. Louis, Missouri 63104 / US | [2023/33] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2023/33] | Application number, filing date | 21878345.4 | 05.10.2021 | [2023/33] | WO2021US53537 | Priority number, date | US202063089122P | 08.10.2020 Original published format: US 202063089122 P | [2023/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022076385 | Date: | 14.04.2022 | Language: | EN | [2022/15] | Type: | A1 Application with search report | No.: | EP4225352 | Date: | 16.08.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.04.2022 takes the place of the publication of the European patent application. | [2023/33] | Search report(s) | International search report - published on: | US | 14.04.2022 | (Supplementary) European search report - dispatched on: | EP | 08.12.2023 | Classification | IPC: | A61K38/28, A61P3/10, A61P5/50, C07K14/62, G01N33/68, A61K39/00, A61K9/06, A61P3/08 | [2024/02] | CPC: |
A61P3/10 (EP,US);
A61K38/28 (EP,US);
A61K39/0008 (EP);
A61K47/02 (US);
A61K47/10 (US);
A61K9/006 (US);
A61P3/08 (EP);
A61P5/50 (EP);
A61K2039/577 (EP);
A61K9/06 (EP)
(-)
|
| Former IPC [2023/33] | A61K38/28, A61P3/10, A61P5/50, C07K14/62, G01N33/68 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/33] | Title | German: | VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG UND PRÄVENTION VON TYP-1-DIABETES | [2023/33] | English: | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES | [2023/33] | French: | MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PRÉVENTION DU DIABÈTE DE TYPE 1 | [2023/33] | Entry into regional phase | 30.03.2023 | National basic fee paid | 30.03.2023 | Search fee paid | 30.03.2023 | Designation fee(s) paid | 30.03.2023 | Examination fee paid | Examination procedure | 30.03.2023 | Examination requested [2023/33] | 10.10.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 02.05.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]DE20021079U (LILLY CO ELI [US]) [Y] 1-15 * the whole document * * example -; claim - *; | [XPY]WO2021113136 (DR MARY MORRIS & ASS LLC [US]) [XP] 1-15 * the whole document * * figure -; example -; claim - * [Y] 1-15; | [Y] - Carolin Daniel ET AL, "Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope", The Journal of Experimental Medicine, vol. 208, doi:10.1084/jem.20110574, (20110620), pages 1501 - 1510, URL: http://jem.rupress.org/content/jem/208/7/1501.full.pdf, (20180416), XP055467409 [Y] 1-15 * the whole document * * figure - * DOI: http://dx.doi.org/10.1084/jem.20110574 | [Y] - BERGMAN MARIE-LOUISE ET AL, "Tolerogenic insulin peptide therapy precipitates type 1 diabetes", JOURNAL OF EXPERIMENTAL MEDICINE, US, vol. 214, no. 7, doi:10.1084/jem.20160471, ISSN 0022-1007, (20170523), pages 2153 - 2156, URL: https://rupress.org/jem/article-pdf/214/7/2153/1757913/jem_20160471.pdf, XP093102101 [Y] 1-15 * the whole document * * figure 1 * DOI: http://dx.doi.org/10.1084/jem.20160471 | [Y] - SAPORTA DIEGO, "Sublingual Immunotherapy: A Useful Tool for the Allergist in Private Practice", BIOMED RESEARCH INTERNATIONAL, vol. 2016, doi:10.1155/2016/9323804, ISSN 2314-6133, (20160101), pages 1 - 6, URL: http://downloads.hindawi.com/journals/bmri/2016/9323804.pdf, XP093102104 [Y] 1-15 * the whole document * * page 3; compound glycerin * DOI: http://dx.doi.org/10.1155/2016/9323804 | [Y] - AL-WAILI NOORI S. D., "Sublingual Human Insulin for Hyperglycaemia in Type I Diabetes", JPMA, vol. 49, no. 7, (19990101), pages 167 - 169, URL: https://www.jpma.org.pk/PdfDownload/3447.pdf, XP093102098 [Y] 1-15 * the whole document * * abstract * | [Y] - PATIL NILAM H. ET AL, "Insulin-loaded alginic acid nanoparticles for sublingual delivery", DRUG DELIVERY, US, (20140605), vol. 23, no. 2, doi:10.3109/10717544.2014.916769, ISSN 1071-7544, pages 429 - 436, XP093102371 [Y] 1-15 * the whole document * * page 431 * DOI: http://dx.doi.org/10.3109/10717544.2014.916769 | [T] - IMRAN MOHAMMED RASHEEDUDDIN ET AL, "Immunologic Desensitisation of Allergens and its Impact on Insulin Use in Type 1 Diabetes Mellitus: A Case Report", JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, (20230101), doi:10.7860/JCDR/2023/62134.17995, ISSN 2249-782X, XP093102618 [T] 1-15 * the whole document * DOI: http://dx.doi.org/10.7860/JCDR/2023/62134.17995 | [Y] - JIN JAY J ET AL, "Sublingual Immunotherapy Dosing Regimens: What Is Ideal?", vol. 5, no. 1, doi:10.1016/J.JAIP.2016.09.027, ISSN 2213-2198, (20161231), pages 1 - 10, THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY : AN OFFICIAL JOURNAL OF AAAAI, AMERICAN ACADEMY OF ALLERGY ASTHMA & IMMUNOLOGY, ELSEVIER BV, NL, URL: https://api.elsevier.com/content/article/PII:S2213219816304731?httpAccept=text/xml, XP009536844 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.jaip.2016.09.027 | International search | [XY]WO2017122180 (INTREXON ACTOBIOTICS N V [BE]) [X] 1-3 * entire document * [Y] 4-9; | [Y] - Harrison et al., "Pancreatic β-Cell Function and Immune Responses to Insulin After Administration of Intranasal Insulin to Humans At Risk for Type 1 Diabetes", Diabetes Care, (20041001), vol. 27, no. 10, pages 2348 - 2355, XP055934927 [Y] 4-7 * entire document * | [Y] - Jin Jay J., Li James T., Klimek Ludger, Pfaar Oliver, "Sublingual Immunotherapy Dosing Regimens: What Is Ideal?", The Journal of Allergy and Clinical Immunology: In Practice, NL , (20161231), vol. 5, no. 1, doi:10.1016/j.jaip.2016.09.027, ISSN 2213-2198, pages 1 - 10, XP009536844 [Y] 8,9 * entire document * DOI: http://dx.doi.org/10.1016/j.jaip.2016.09.027 |